In the evolving landscape of biomedical innovation, exosomes have emerged as one of the most promising tools for next-generation therapies. These nanoscale, membrane-bound vesicles, naturally secreted by cells, play a critical role in intercellular communication. Because of their inherent ability to shuttle biomolecules like RNA, proteins, and lipids between cells, exosomes have captivated the attention of researchers and biotech companies for their vast potential in therapeutic applications.
From targeted drug delivery to cancer therapy, gene editing, vaccine development, and tissue regeneration, exosomes are transforming the biomedical field. Among their most exciting uses today is their customization—creating “designer exosomes” with specific functionalities tailored to treat complex diseases more precisely and effectively.
Why Exosomes as Drug Delivery Vehicles?
Exosomes are ideal delivery vehicles due to their biocompatibility, low immunogenicity, and ability to cross biological barriers like the blood-brain barrier. Unlike synthetic nanoparticles, exosomes are naturally occurring and derived from human cells, making them safer and more efficient for delivering therapeutic payloads.
Today, designer exosomes are being developed to deliver drugs and functional molecules to specific areas of the body, including wounds, neurons, and the cardiovascular system. These targeted approaches open the door to treating neurological disorders, heart disease, chronic wounds, and even cancer with greater precision and fewer side effects.
Two Key Strategies: Parental Cell-Based and Direct Engineering
To functionalize exosomes for therapeutic use, scientists have developed two core engineering strategies:
1. Parental Cell-Based (Pre-Isolation) Engineering
In this approach, the exosome-producing cells—often stem cells or other human-derived cells—are genetically modified or otherwise manipulated before exosomes are harvested. This allows researchers to embed specific therapeutic molecules inside the exosomes (in the lumen) or display them on the exosome surface. Common tools used in this approach include:
-
WW-tags: Protein tags that help anchor therapeutic proteins to exosomes.
-
EXPLORs (Exosomes for Protein Loading via Optically Reversible Protein-Protein Interaction): A technique to actively load proteins into exosomes through light-controlled mechanisms.
This method allows for controlled and uniform loading of cargo, which is especially important in applications such as gene therapy and immune modulation.
2. Direct (Post-Isolation) Exosome Engineering
Once exosomes are isolated from their parental cells, they can be further modified using chemical or physical techniques. For example:
-
Click chemistry: A fast and selective chemical reaction used to attach drugs or targeting ligands to the surface of exosomes.
-
Cloaking: A method of hiding or modifying surface proteins on exosomes to evade the immune system or to alter targeting properties.
This method is often faster and more flexible than parental cell-based engineering and is commonly used when researchers need to test multiple variations of engineered exosomes for optimization.
The Development of Designer Exosomes
The development of designer exosomes is still in its early stages, but several startups and biotech firms are pushing the field forward. Exciting examples of this work include:
Anjarium Biosciences is developing engineered extracellular-vesicle technologies for the delivery of RNA and other genetic medicines through its proprietary EXOtic™ platform.
Aruna Bio is developing neural-derived exosomes for treating neurological disorders, with a lead candidate targeting stroke recovery.
Aegle Therapeutics is using mesenchymal stem cell-derived exosomes for dermatological conditions and wound healing, including severe burns and rare skin diseases.
Capricor Therapeutics is developing precision-engineered exosomes through its proprietary StealthX™ platform. The technology is designed to alter the exosome surface with proteins, ligands, or antigens while also enabling therapeutic cargo to be loaded inside the vesicles. Capricor is exploring the platform for targeted delivery of proteins, nucleic acids, and small molecules, as well as for exosome-based vaccines.
Codiak BioSciences pioneered the engEx™ platform, which enabled researchers to engineer exosomes for controlled cargo loading and surface modification. Although Codiak is no longer operating as an independent company, its technology continues to influence the field. In 2023, Evox Therapeutics acquired Codiak’s engEx-AAV™ technology and related intellectual property, adding technology for loading AAV into exosomes to its broader exosome-delivery platform.
EVerZom is developing an integrated exosome platform that encompasses both parental-cell modification and direct exosome engineering. Its technology can modify source cells to alter the therapeutic properties of their exosomes and can also load exosomes with molecules such as RNA, proteins, and chemotherapy agents. The company is additionally developing manufacturing and formulation technologies intended to improve the scalability, stability, and delivery of exosome-based therapeutics.
Evox Therapeutics is developing exosome-based genetic medicines through its proprietary ExoEdit® platform, which combines exosome delivery with genome-editing technologies. It is focused on using engineered exosome-based delivery to transport CRISPR-derived editing tools into specific organs and cells, with a focus on difficult-to-treat neurological diseases. Evox has also acquired technology developed by Codiak BioSciences for loading AAV into exosomes, expanding its capabilities in engineered exosome delivery.
MDimune has developed the BioDrone™ platform to produce cell-derived vesicles for targeted drug delivery across various diseases, including cancer and inflammation.
Oasis Biotech is engineering exosomes for targeted immune modulation and drug delivery in oncology and autoimmune disease.
Shine-On Biomedical is developing targeted exosome therapeutics designed to direct therapeutic payloads toward specific cell types. Its SOB100 platform uses exosomes engineered with an HLA-G-specific nanobody to target HLA-G-expressing cells, particularly tumor cells. The company’s pipeline also includes exosomal doxorubicin, exosomal microRNA, and genetically engineered stem-cell-derived exosomes. SOB100 has progressed into clinical development, making Shine-On Biomedical one of the more advanced examples of targeted designer exosomes.
RION is developing next-generation platelet-derived exosome technology designed to deliver therapeutic cargo. Its PEP™ platform is being developed to encapsulate molecules including proteins, RNA, DNA, and small-molecule drugs within exosomes, with the goal of improving delivery, bioavailability, and cellular uptake. This approach illustrates how naturally derived exosomes can be further engineered to function as customizable drug-delivery vehicles.
Xollent Biotech engineers exosomes with brain-targeting ligands to deliver therapeutics across the blood-brain barrier for neurological applications.
Of course, there are other innovators working in this field as well. As these companies bring exosome-based products into clinical trials, we can expect to see a wave of personalized and highly targeted therapies that could reshape how we treat chronic and life-threatening conditions.
Ready to learn about this rapidly expanding market area? View the “The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2026-27.”
